XNYS · Drug Manufacturers - General
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$166.08-0.04%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
58/100
Positive
Score components
TickerWhale View
Astrazeneca scores 58 out of 100 overall, which we rate positive. Quality & growth is its strongest area and Valuation its weakest.
What helps
- Quality & growth
- Risk
- Sentiment Signal
What to watch
- Technical
- Valuation
Quality & growth
30%82Strong
- Revenue growth 8.6%
- EPS growth 25.8%
Valuation
25%35Weak
- P/E 24.8
- EV/Sales 4.7
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
#46 by market cap in our coverage · ~96,100 employees · Listed 2009-10-23 · www.astrazeneca.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#60 / 139sector rank by TickerWhale Score
TickerWhale Score 58 vs sector average 55.1 (+2.9)
Revenue growth (industry)Top 36%
Gross margin (industry)Top 18%
Return on equity (industry)Top 60%
P/E (industry)Cheaper than 70%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
47/100Moderate vs universe
Ranks 47th of 100 covered names on our technical composite — the composite itself scores 46/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 2 sell · 3 neutral of 8 votes
TickerWhale rates AZN's technical setup middling — 47th percentile of the covered universe. Classic chart indicators lean buy — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
5 / 9constructive
- vs 200-day-9.2%
- vs 50-day+1.1%
Momentum
Mixed
- RSI (14)55 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rsell
Trend
Mixed
- ADX (14) trend strength11· weak trend
- MACD (12,26,9)buy(histogram 0.726)
How the classic verdict is reached
Moving averages (9) agree on buy — 5 buy vs 3 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 2 sell · 3 neutral.
Result — 3 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)24.8
- P/S (TTM)4.2
- P/B5.2
- EV/EBITDA13.9
- EV/Sales4.7
- PEG0.96
Profitability & returns
- Gross margin81.9%
- Net margin17.0%
- ROE21.4%
- Debt/Equity0.64
Growth
- Revenue growth (YoY)8.6%
- EPS growth (YoY)25.8%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $259.3B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $58.7B | $54.1B | $45.8B |
| Gross profit | $48.1B | $43.9B | $37.5B |
| Operating income | $13.7B | $10.0B | $8.2B |
| Net income | $10.2B | $7.0B | $6.0B |
| EPS (diluted) | $6.54 | $4.50 | $3.81 |
| Free cash flow | $11.8B | $10.0B | $9.1B |
| Cash | $5.7B | $5.5B | $5.8B |
| Total debt | $29.6B | $30.3B | $28.6B |
| Equity | $48.7B | $40.8B | $39.1B |
| Net debt | $23.9B | $24.8B | $22.8B |
| Debt / equity | 0.61 | 0.74 | 0.73 |
| Liabilities / assets | 0.57 | 0.61 | 0.61 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AZNCurrentAstrazeneca | 58 | 46 | 24.8 | — | 5.2 | 4.7 | $166.08 | -0.04% | +8.6% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.